It was a peculiar week for pharma companies as shares of Dr Reddy’s tanked over 13% while that of Sun Pharma jumped 11%. Going by the extreme reactions, it is tough to understand the near-term outlook of the sector. One set of investors believes pharma has enough structural tailwinds, while others are worried that the Covid-induced demand would soon vanish.
In today’s special podcast with independent market expert Rajiv Nagpal, let’s take a deep dive into pharma stocks to understand opportunities and threats in this defensive pack.
Listen in.
Welcome to the show Mr Nagpal.
1) What is your reading from the results and concalls of pharma companies like Dr Reddy’s, Sun Pharma and Laurus Labs? What are the major pain points?
2) How big a threat is the slowing down of Covid-related demand and the coming back of USFDA audits to earnings of pharma companies?
3) Do you think the market over-reacted last week when it came to Dr Reddy’s?
4) Is it a good time to buy the dip in pharma stocks? Is there any scope for further rerating?
Thank you Mr Nagpal. That’s all in today’s special podcast. But do keep checking this space for more such interesting content. Good bye!
